Literature DB >> 21607667

The combined effects of oncolytic reovirus plus Newcastle disease virus and reovirus plus parvovirus on U87 and U373 cells in vitro and in vivo.

Muhannad Alkassar1, Barbara Gärtner, Klaus Roemer, Friedrich Graesser, Jean Rommelaere, Lars Kaestner, Isabelle Haeckel, Norbert Graf.   

Abstract

Previous results had documented oncolytic capacity of reovirus, parvovirus and Newcastle disease virus (NDV) on several tumor cell types. To test whether combinations of these viruses may increase this capacity, human U87- and U373-glioblastoma cells, in vitro or xenografted into immuno-compromised mice, were subjected to simultaneous double infections and analyzed. Our results show that reovirus (serotype-3) plus NDV (Hitcher-B1) and reovirus plus parvovirus-H1 lead to a significant increase in tumor cell killing in vitro in both cell lines (Kruskal-Wallis test, P < 0.01) and in vivo. Immunofluorescence and flow cytometry analyses demonstrated the simultaneous replication of the viruses in nearly all cells (>95%) after combined infection. These data thus indicate that a synergistic anti-tumor effect can be achieved by the combined infection with oncolytic viruses.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21607667     DOI: 10.1007/s11060-011-0606-5

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  56 in total

1.  Correlation between interferon sensitivity of reovirus isolates and ability to discriminate between normal and Ras-transformed cells.

Authors:  Penny Rudd; Guy Lemay
Journal:  J Gen Virol       Date:  2005-05       Impact factor: 3.891

Review 2.  Viruses in the treatment of malignant glioma.

Authors:  Richard G Everson; Mathias Gromeier; John H Sampson
Journal:  Expert Rev Neurother       Date:  2007-04       Impact factor: 4.618

3.  Cytoplasmic trafficking of the canine parvovirus capsid and its role in infection and nuclear transport.

Authors:  M Vihinen-Ranta; W Yuan; C R Parrish
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

4.  Involvement of the interferon-regulated antiviral proteins PKR and RNase L in reovirus-induced shutoff of cellular translation.

Authors:  Jennifer A Smith; Stephen C Schmechel; Bryan R G Williams; Robert H Silverman; Leslie A Schiff
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

5.  Reovirus core protein mu2 determines the filamentous morphology of viral inclusion bodies by interacting with and stabilizing microtubules.

Authors:  John S L Parker; Teresa J Broering; Jonghwa Kim; Darren E Higgins; Max L Nibert
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

6.  Morbidity in immunosuppressed (SCID/NOD) mice treated with reovirus (dearing 3) as an anti-cancer biotherapeutic.

Authors:  Steve D Loken; Kara Norman; Kensuke Hirasawa; Michael Nodwell; Wanda M Lester; Douglas J Demetrick
Journal:  Cancer Biol Ther       Date:  2004-08-10       Impact factor: 4.742

Review 7.  Long-term survival with glioblastoma multiforme.

Authors:  Dietmar Krex; Barbara Klink; Christian Hartmann; Andreas von Deimling; Torsten Pietsch; Matthias Simon; Michael Sabel; Joachim P Steinbach; Oliver Heese; Guido Reifenberger; Michael Weller; Gabriele Schackert
Journal:  Brain       Date:  2007-09-04       Impact factor: 13.501

8.  Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells.

Authors:  Roberto R Rosato; Jorge A Almenara; Yun Dai; Steven Grant
Journal:  Mol Cancer Ther       Date:  2003-12       Impact factor: 6.261

9.  Formation of the factory matrix is an important, though not a sufficient function of nonstructural protein mu NS during reovirus infection.

Authors:  Michelle M Arnold; Kenneth E Murray; Max L Nibert
Journal:  Virology       Date:  2008-04-18       Impact factor: 3.616

10.  The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro.

Authors:  T Alain; M Kim; R N Johnston; S Urbanski; A E Kossakowska; P A Forsyth; P W K Lee
Journal:  Br J Cancer       Date:  2006-10-03       Impact factor: 7.640

View more
  12 in total

Review 1.  Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity.

Authors:  Jun Gong; Esha Sachdev; Alain C Mita; Monica M Mita
Journal:  World J Methodol       Date:  2016-03-26

2.  Pathogen response-like recruitment and activation of neutrophils by sterile immunogenic dying cells drives neutrophil-mediated residual cell killing.

Authors:  Abhishek D Garg; Lien Vandenberk; Shentong Fang; Tekele Fasche; Sofie Van Eygen; Jan Maes; Matthias Van Woensel; Carolien Koks; Niels Vanthillo; Norbert Graf; Peter de Witte; Stefaan Van Gool; Petri Salven; Patrizia Agostinis
Journal:  Cell Death Differ       Date:  2017-02-24       Impact factor: 15.828

Review 3.  Replicating poxviruses for human cancer therapy.

Authors:  Manbok Kim
Journal:  J Microbiol       Date:  2015-04-08       Impact factor: 2.902

4.  Current status of gene therapy for brain tumors.

Authors:  Andrea M Murphy; Samuel D Rabkin
Journal:  Transl Res       Date:  2012-12-11       Impact factor: 7.012

5.  Reovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia.

Authors:  Kathryn Hall; Karen J Scott; Ailsa Rose; Michael Desborough; Kevin Harrington; Hardev Pandha; Christopher Parrish; Richard Vile; Matt Coffey; David Bowen; Fiona Errington-Mais; Alan A Melcher
Journal:  Biores Open Access       Date:  2012-01

Review 6.  Immune Suppression during Oncolytic Virotherapy for High-Grade Glioma; Yes or No?

Authors:  Carolien A E Koks; Steven De Vleeschouwer; Norbert Graf; Stefaan W Van Gool
Journal:  J Cancer       Date:  2015-01-15       Impact factor: 4.207

Review 7.  Brain Tumor Immunotherapy: What have We Learned so Far?

Authors:  Stefaan Willy Van Gool
Journal:  Front Oncol       Date:  2015-06-17       Impact factor: 6.244

Review 8.  Naturally occurring reoviruses for human cancer therapy.

Authors:  Manbok Kim
Journal:  BMB Rep       Date:  2015-08       Impact factor: 4.778

Review 9.  Targeting Autophagy for Oncolytic Immunotherapy.

Authors:  Lulu Hu; Ke Jiang; Chan Ding; Songshu Meng
Journal:  Biomedicines       Date:  2017-01-11

10.  Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy.

Authors:  Markus Vähä-Koskela; Siri Tähtinen; Susanna Grönberg-Vähä-Koskela; Kristian Taipale; Dipongkor Saha; Maiju Merisalo-Soikkeli; Marko Ahonen; Noora Rouvinen-Lagerström; Mari Hirvinen; Ville Veckman; Sampsa Matikainen; Fang Zhao; Päivi Pakarinen; Jarmo Salo; Anna Kanerva; Vincenzo Cerullo; Akseli Hemminki
Journal:  Mol Ther Oncolytics       Date:  2015-01-07       Impact factor: 7.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.